Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-12-02
1997-10-21
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540473, 540587, 546245, 548568, 544349, C07D48704, C07D47104, C07D 3155, C07D 31495
Patent
active
056796790
ABSTRACT:
Certain aralkyl diazabicyloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein: each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from the group consisting of hydrido, loweralkyl, benzyl and haloloweralkyl;
REFERENCES:
patent: 4204003 (1980-05-01), Szmuszkovicz
patent: 4463013 (1984-07-01), Collins et al.
patent: 4801604 (1989-01-01), VonVoightlander et al.
patent: 5346908 (1994-09-01), Bonen
Aram et al., J. Pharmacol. Exp. Ther., 248, 320-328 (1989) Abstract only.
Bailey et al., Eur. J. Pharmacol., 240, 243-250 (1993).
Canoll et al., J. Neurosci. Res., 24, 311-328 (1989) Abstract only.
Cook et al., J. Pharmacol. Exp. Ther., 263, 1159-1166 (1992) Abstract only.
DeCoster et al., Brain Res., 671, 45-53 (1995) Abstract only.
DeHaven-Hudkins et al., Life Sci., 56, 1571-1576 (1995).
Itzhak et al., FASEB J., 3, 1868-1872 (1989).
Kirk et al., J. Pharmacol. Exp. Ther., 271, 1080-1085 (1994) Abstract only.
Klein et al., J. Pharmacol. Exp. Ther., 260, 990-999 (1992) Abstract only.
Klein et al., Eur. J. Pharmacol., 254, 239-248 (1994).
Lasage et al., Synapse, 20, 156-64 (1995) Abstract only.
Loscher et al., Eur. J. Pharmacol., 238, 191-200 (1993).
Lysko et al., Stroke, 23, 414-419 (1992) Abstract only.
Lysko et al., Stroke, 23, 1319-1323 (1992) Abstract only.
Pontecorvo et al., Brain Res. Bull., 26, 461-465 (1991) Abstract only.
Reddy et al., J. Med, Chem., 37, 260-267 (1994) Abstract only.
Roth et al., Eur. J. Pharmacol., 236, 327-331 (1993).
Takahashi et al., Stoke, 26, 1676-1682 (1995) Abstract Only.
Tortella et al., Trends Pharmacol. Sci., 10:501-507 (1990).
Tortella et al., Trends Pharmacol. Sci., 11:146-147 (1990).
Weissman et al., Biol. Psych., 29, 41-54 (1991).
Witkin et al., J. Pharmacol. Exp. Ther., 266, 473-482 (1993).
Bellville, Clin Pharm & Ther. 9, 142 (1968).
Clissold, J. Pharm. & Exp. Therapeutics 265, 876 (1993.
Forrest, Clin. Pharm. Ther. 10, 468 (1969).
Walker, Clin. Neuropharmacology, 12, 322(1989).
Contreres, Brain Res 546, 79 (1991).
Pontecorvo, Brain Res Bulletin, 26, 461-465 (1991).
Simon, Science 226, 850 (1984).
Goldberg, J. Pharm. & Exp. Therap. 243, 784(1987).
De Coster, Brain Res 671, 45(1995).
Golzalez-Alrear, Brain Res 673, 61 (1995).
Rogawski, Tips 14, 325 (1993).
Chouinard, Psychopharmacology 84, 282(1984).
Nogawski, J. Pharm. Exp. Therapeutics 259, 30(1991.
Rogawski, Drugs 44, 279 (1992).
Lohner, Neurosci Letters 117, 169 (1990).
Gonzalez-Alvear, J. Pharm Exp. Therapeutics 271, 212(1994).
de Costa, J Med Chem 35, 4334 (1992).
de Costa, J. Med Chem 36, 2311 (1993).
Cook, J. Pharm Exp Ther. 263, 1159(1992).
Abstract of Izhak et al, FASEB J 3(7) p. 1868 (1989).
Abstract of Bailey et al, Eur. J. Pharmacol 240, p. 243 (1993).
Abstract of Weissman et al, Biol Psychiatry 29, p. 41(1991).
Clissold, J. Pharm. Exp. Thera. 265, 876(1993).
"Sigma Receptors" (Izhak, ed, Academic Press 1994), pp. 191-204.
Gewirtz, Neuropsychopharmacology 10, 37(1994).
Derwent Abstract for WO92/00128 (1992).
Hadkins, Life Sci 49, 1229 (1992).
Rothman, et al.; Annals of Neurology, 19(2): 105-11 (1986).
Carter, et al.; J. Pharm. Exp. Ther., 247(3): 1222-32 (1988).
Gilman, et al.; The Pharmacological Basis of Therapeutics, 7th ed., p. 404 MacMillan (1985).
Parsons, et al.; Neuropharm., 25(2): 217-20 (1986).
Lason, et al.; Brain Res., 482: 333-39 (1989).
de Costa, et al.; J. Med. Chem., 32(8): 1996-1002 (1989).
Long, et al.; Soc. Neurosci. Abs., 16: 1122, abs 461.4 (1990).
Contreras, et al.; Brain Res., 546:7-79-82 (1991).
Scopes, et al.; J. Med. Chem., 35: 490-501 (1992).
de Costa, et al.; J. Med. Chem., 35(1): 38-47 (1992).
Radesca, et al.; J. Med. Chem., 34(10): 3058-65 (1991).
Giardina, "Analgesici Oppioidi Kappa: Sintesi E Relazioni Struttura-Attivita' Di Piperidine Sostituite", Biosistemi Come Targets Farmacologici Recettori Peptidergici, pp. 21-63(1992).
M. Rees, "Synthesis & Biological Activity of Kappa-Opioid Agonists Leading to the Selection of CI-977 (Enadoline) for Clinical Investigation", Biosistemi Come Targets Farmacologici, Recettori Peptidergici, pp. 65-101. (1992).
N. Ronsisvale; "Requisiti Strutturali Per I Liganti Oppioidi: E'Possibile Modulare La Selecttivita?", Biosistemi Come Targets Farmacologici Recettori Peptidertici, pp. 102-133. (1992).
O. Hudkins, et al.; Life Sci., 49(17): 1229-35 (1991).
Bowen Wayne
de Costa Brian R.
Dominguez Celia
He Xiao-Shu
Rice Kenner C.
Berch Mark L.
The United States of America as represented by the Department of
LandOfFree
Aralkyl diazabicycloalkane derivatives for CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aralkyl diazabicycloalkane derivatives for CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl diazabicycloalkane derivatives for CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1006966